Urgent

Methotrexate pneumonitis

Acute DMARD lung injury · Rheumatology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

An idiosyncratic hypersensitivity-type acute interstitial pneumonitis occurring in patients on methotrexate, usually within the first year. Presents with subacute dry cough, progressive breathlessness, fever and hypoxaemia, and can progress to respiratory failure if the drug is not stopped.

Red flags

  • Rapidly worsening hypoxaemia
  • Respiratory rate >30 or exhaustion
  • Diffuse bilateral infiltrates on imaging
  • Fever with failure to respond to antibiotics
  • Rising oxygen requirement despite treatment

Assessment

Differential diagnosis

  • Infective pneumonia (incl. PJP)
  • Rheumatoid / connective-tissue-disease ILD
  • Pulmonary oedema / cardiac failure
  • Pulmonary embolism
  • Other drug-induced pneumonitis (leflunomide, biologics)
  • Disease-related alveolitis

Investigations

  • Chest radiograph and high-resolution CT (diffuse ground-glass / interstitial infiltrates)
  • ABG / oxygen saturation (hypoxaemia)
  • FBC, CRP, LDH, renal and liver function
  • Infective screen: cultures, respiratory viral PCR, PJP (beta-D-glucan, induced sputum)
  • Pulmonary function tests (restrictive, reduced transfer factor)
  • Bronchoalveolar lavage to exclude infection if diagnosis uncertain

Management

  • Stop methotrexate immediately
  • Give supplemental oxygen to maintain target saturations and support breathing
  • Exclude infection vigorously - PJP and bacterial pneumonia mimic methotrexate pneumonitis
  • Admit and start empirical antimicrobials/co-trimoxazole until infection excluded
  • Start corticosteroids once infection is reasonably excluded or covered
  • Give folinic acid rescue if marrow suppression coexists
  • Monitor gas exchange; escalate to HDU/ICU and ventilatory support if deteriorating
  • Document methotrexate as a cause and avoid rechallenge; liaise with rheumatology for alternative DMARD

Drugs & doses

Prednisolone — 0.5-1 mg/kg/day PO (up to 60 mg) with taper
Methylprednisolone — 500 mg-1 g IV OD x3 for severe hypoxaemic disease
Co-trimoxazole — 120 mg/kg/day IV in divided doses if PJP suspected/treated
Folinic acid — 15 mg IV/PO 6-hourly if concurrent methotrexate toxicity
Oxygen — titrated to SpO2 94-98% (88-92% if COPD risk)

Disposition

Admit (HDU if hypoxaemic); stop methotrexate, cover infection and start steroids with respiratory/rheumatology input.

Complications & pitfalls

  • Acute respiratory distress syndrome
  • Respiratory failure requiring ventilation
  • Pulmonary fibrosis
  • Superimposed opportunistic infection
  • Death (mortality can approach 15-20% in severe cases)

Exam pearls

  • Can occur at any dose and at any time but most common in the first year
  • Distinguishing from infection (especially PJP) is the key clinical challenge - treat both if unsure
  • Peripheral eosinophilia and BAL lymphocytosis support the diagnosis
  • Never rechallenge after confirmed methotrexate pneumonitis

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.